In addition to leveraging a pipeline of complex generics across its markets while focusing on OTC, Dr. Reddy's chairman K Satish Reddy said the branded generics would be one of the ways the company drives growth in the coming years.
Reuters is reporting that the FDA’s Arthritis Advisory Board has unanimously recommended Amgen’s biosimilar of AbbVie’s Humira, ABP 501. The panel said that the drug was similar in safety and effectiveness to Humira for rheumatoid arthritis and plaque psoriasis, and it recommended that the biosimilar should also be approved for Crohn’s disease in adults and ulcerative colitis. (Reuters)
The move is aimed at Nichi-Iko becoming one of the top 10 global generics leaders, and the companies said acquiring Sagent will boost Nichi-Iko’s ability to commercialize its biosimilar pipeline and increase its presence in injectables.